Stewart W K, Fleming L W, Shepherd A M
Nephron. 1976;17(2):121-9. doi: 10.1159/000180717.
Patients with chronic renal failure who were on maintenance haemodialysis, were given monthly 600 mg iron intravenously as iron-dextran complex to a body replacement total of 5-6 g iron. Those patients who had been on maintenance haemodialysis for a long period and had received numerous blood transfusions failed to show a rise in haemoglobin levels. Those patients who received iron from the commencement of maintenance dialysis, and who had not received blood transfusions, showed a significant increase in haemoglobin concentrations which has been maintained for more than 18 months after iron therapy ceased, despite a concurrent decrease in serum iron concentrations. Pre-treatment and post-treatment levels of serum iron are not of predictive value for the success of iron treatment, neither for the haemoglobin nor the serum iron response. A body replacement dose of iron given intravenously over a year benefits the majority of patients on maintenance haemodialysis and is recommended for the treatment of their anaemia.
接受维持性血液透析的慢性肾衰竭患者，每月静脉注射600毫克右旋糖酐铁复合物，以使体内铁总量补充至5 - 6克。那些长期接受维持性血液透析且多次输血的患者，血红蛋白水平未能升高。而那些从开始维持性透析就接受铁剂治疗且未输血的患者，血红蛋白浓度显著升高，并且在停止铁剂治疗后，尽管血清铁浓度同时下降，但血红蛋白浓度仍维持了超过18个月。血清铁的治疗前和治疗后水平对于铁剂治疗的成功与否并无预测价值，无论是对血红蛋白还是血清铁的反应均如此。一年内静脉给予的体内铁补充剂量对大多数接受维持性血液透析患者有益，推荐用于治疗他们的贫血。
